NF-κB signalling proteins p50/p105, p52/p100, RelA, and IKKε are over-expressed in oesophageal squamous cell carcinomas

Pathology

Volumn 41, Issue 7, 2009, Pages 622-625

  Kang, Mi Ran ^a   Kim, Min Seop ^a   Kim, Sung Soo ^a   Ahn, Chang Hyeok ^a   Yoo, Nam Jin ^a   Lee, Sug Hyung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Expression; IKK ; NF B; Oesophageal cancer; P50 100; P52 p100; RelA

Indexed keywords

I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P100; PROTEIN P105; PROTEIN P50; PROTEIN P52; TRANSCRIPTION FACTOR RELA; I KAPPA B KINASE; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CYTOPLASM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; AGED; CANCER INVASION; CELL NUCLEUS; ENZYME IMMUNOASSAY; ESOPHAGUS; ESOPHAGUS TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CYTOPLASM; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; I-KAPPA B KINASE; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NF-KAPPA B P50 SUBUNIT; NF-KAPPA B P52 SUBUNIT; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTOR RELA; TUMOR MARKERS, BIOLOGICAL;

EID: 72749126288     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313020903257756     Document Type: Article

References (21)

1. Aggarwal BB. Nuclear factor-kB: the enemy within. Cancer Cell 2004; 6: 203-208
2. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 2006; 13: 759-772
3. Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 25: 6817-6830
4. Adli M, Baldwin AS. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 2006; 281: 26976-26984
5. Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129: 1065-1079
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
7. Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factorkappaB/ Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997; 100: 2952-2960
8. Dejardin E, Deregowski V, Chapelier M, et al. Regulation of NFkappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 1999; 18: 2567-2577
9. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5: 119-127
10. Visconti R, Cerutti J, Battista S, et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 1997; 15: 1987-1994
11. Ross JS, Kallakury BV, Sheehan CE, et al. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 2004; 10: 2466-2472
12. Tian F, Zang WD, Hou WH, Liu HT, Xue LX. Nuclear factor-kB signaling pathway constitutively activated in esophageal squamous cell carcinoma cell lines and inhibition of growth of cells by small interfering RNA. Acta Biochim Biophys Sin (Shanghai) 2006; 38: 318-326
13. Liu JF, Zhu GJ, Jamieson GG, et al. NS-398 induces apoptosis in human esophageal cancer cells through inhibition of NF-kappaB downstream regulation of cyclooxygenase-2. Cancer Invest 2009; 27: 17-23.
14. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847
15. Yang GZ, Li L, Ding HY, Zhou JS. Cyclooxygenase-2 is overexpressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-kappaB: an immunohistochemical study. Exp Mol Pathol 2005; 79: 214-218
16. Abdel-Latif MM, O'Riordan J, Windle HJ, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004; 239: 491-500.
17. O'Riordan JM, Abdel-latif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia- adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005; 100: 1257-1264
18. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 97-102.
19. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116-1119
20. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-144
21. Courtois G, Gilmore TD. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006; 25: 6831-6843